Phase III clinical trial - Sein métastatique triple négatif

IMPassion 132 (MO39193)
Sein métastatique triple négatif
Ouvert depuis le: 11.29.2022
Site: Paris
Public cible
A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study Of The Efficacy And Safety Of Atezolizumab Plus Chemotherapy For Patients With Early Relapsing Recurrent (Inoperable Locally Advanced Or Metastatic) Triple-Negative Breast Cancer
Description de l'essai

This study will evaluate the efficacy and safety of atezolizumab plus chemotherapy compared with placebo plus chemotherapy in patients with inoperable recurrent triple-negative breast cancer (TNBC).